Cargando…

Anticoagulation for Atrial Fibrillation in Cirrhosis of the Liver: Are Low‐Dose Non‐Vitamin K Oral Anticoagulants a Reasonable Alternative to Warfarin?

See Article by Lee et al

Detalles Bibliográficos
Autores principales:	Gallagher, Celine, Sanders, Prashanthan, Wong, Christopher X.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6474927/ https://www.ncbi.nlm.nih.gov/pubmed/30834801 http://dx.doi.org/10.1161/JAHA.119.012102

Ejemplares similares

Efficacy and safety of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation
por: Friberg, Leif, et al.
Publicado: (2017)

Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients With Intracerebral Hemorrhage
por: Nielsen, Peter Brønnum, et al.
Publicado: (2019)

Risk of Osteoporosis in Patients With Atrial Fibrillation Using Non–Vitamin K Antagonist Oral Anticoagulants or Warfarin
Publicado: (2020)

Risk of Osteoporosis in Patients With Atrial Fibrillation Using Non–Vitamin K Antagonist Oral Anticoagulants or Warfarin
por: Huang, Huei‐Kai, et al.
Publicado: (2020)

Warfarin doses for anticoagulation therapy in elderly patients with chronic atrial fibrillation
por: de Padua Mansur, Antonio, et al.
Publicado: (2012)

Should we shift warfarin to non-vitamin K antagonist oral anticoagulants for patients with atrial fibrillation staying well on warfarin for years?
por: Chao, T, et al.
Publicado: (2023)

Effectiveness and Safety of Non–Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation
por: Lee, Hsin‐Fu, et al.
Publicado: (2019)

Ten years of non-vitamin K antagonists oral anticoagulants for stroke prevention in atrial fibrillation: is warfarin obsolete?
por: Hammwöhner, Matthias, et al.
Publicado: (2020)

Cardiovascular and renal protective effects of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation
por: Choi, Seong Huan, et al.
Publicado: (2022)

Anticoagulation in patients with atrial fibrillation and liver cirrhosis
por: Karapedi, Eleni, et al.
Publicado: (2022)

Veterans Perceptions of Satisfaction and Convenience with Anticoagulants for Atrial Fibrillation: Warfarin versus Direct Oral Anticoagulants
por: Mull, Hillary J, et al.
Publicado: (2020)

Real-world comparison of non-vitamin K antagonist oral anticoagulants and warfarin in Asian octogenarian patients with atrial fibrillation
por: Kwon, Chang Hee, et al.
Publicado: (2016)

Risk of Ischemic Bowel Disease in Patients With Atrial Fibrillation Receiving Warfarin or Non-vitamin K Antagonist Oral Anticoagulants
por: Liao, Jo-Nan, et al.
Publicado: (2022)

Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients without previous oral anticoagulants or stable under warfarin: a nationwide cohort study
por: Liu, Shin-Huei, et al.
Publicado: (2023)

Warfarin anticoagulation in hemodialysis patients with atrial fibrillation: comparison of nephrologist-led and anticoagulation clinic-led management
por: Bahbahani, Hamad, et al.
Publicado: (2018)

Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation
por: Choi, Jiyoon C, et al.
Publicado: (2014)

Levetiracetam and non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and epilepsy: a reasonable combination
por: von Oertzen, Tim J, et al.
Publicado: (2019)

Meta-analysis of the efficacy and safety of non-vitamin K antagonist oral anticoagulants with warfarin in Latin American patients with atrial fibrillation
por: Su, Zhiyu, et al.
Publicado: (2020)

Safety and efficacy of non–vitamin K antagonist oral anticoagulants compared with well-controlled warfarin in Thai patients with atrial fibrillation
por: Yamkasikorn, Janekij, et al.
Publicado: (2022)

Stability of High‐Quality Warfarin Anticoagulation in a Community‐Based Atrial Fibrillation Cohort: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study
por: Dallalzadeh, Liane O., et al.
Publicado: (2016)

Paradoxical Procoagulant Effect of Early Doses of Warfarin: Possible Role of Non-Vitamin K Oral Anticoagulant in Patients with Atrial Fibrillation-Related Stroke
por: Kim, Yesel, et al.
Publicado: (2015)

Safety and effectiveness of anticoagulation with non-vitamin K antagonist oral anticoagulants and warfarin in patients on tuberculosis treatment
por: Lee, Hyun-Jung, et al.
Publicado: (2023)

Low-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
por: Lee, Ki Hong, et al.
Publicado: (2023)

Incidence and predictors of excessive warfarin anticoagulation in patients with atrial fibrillation—The EWA study
por: Jaakkola, Samuli, et al.
Publicado: (2017)

Direct Oral Anticoagulant Adherence of Patients With Atrial Fibrillation Transitioned from Warfarin
por: Pundi, Krishna N., et al.
Publicado: (2021)

Safety of direct oral anticoagulants compared to warfarin in cirrhotic patients with atrial fibrillation
por: Yoo, Seo Yeon, et al.
Publicado: (2022)

Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta‐Analysis
por: Deng, Yuqing, et al.
Publicado: (2019)

Non-vitamin K antagonist oral anticoagulants versus warfarin for cardioversion of atrial fibrillation in clinical practice: A single-center experience
por: Shibata, Naoki, et al.
Publicado: (2017)

Real‐life experience with non‐vitamin K antagonist oral anticoagulants versus warfarin in patients undergoing elective cardioversion of atrial fibrillation
por: Itäinen‐Strömberg, Saga, et al.
Publicado: (2020)

Effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation: a Scandinavian population-based cohort study
por: Halvorsen, Sigrun, et al.
Publicado: (2021)

Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study
por: Nielsen, Peter Brønnum, et al.
Publicado: (2017)

A survey of reasons for continuing warfarin therapy in the era of direct oral anticoagulants in Japanese patients with atrial fibrillation: the SELECT study
por: Ikeda, Takanori, et al.
Publicado: (2018)

Non-vitamin K antagonist oral anticoagulants in cancer patients with atrial fibrillation
por: Undas, Anetta, et al.
Publicado: (2020)

Anticoagulation in atrial fibrillation
por: Steinberg, Benjamin A, et al.
Publicado: (2014)

Asian Patients with Stroke plus Atrial Fibrillation and the Dose of Non-Vitamin K Oral Anticoagulants
por: Bang, Oh Young, et al.
Publicado: (2016)

Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study
por: Larsen, Torben Bjerregaard, et al.
Publicado: (2016)

Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Asians With Atrial Fibrillation: Meta-Analysis of Randomized Trials and Real-World Studies
por: Xue, Zhengbiao, et al.
Publicado: (2019)

Cost-Effectiveness of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation with Edoxaban Compared to Warfarin in Germany
por: Krejczy, Martin, et al.
Publicado: (2015)

Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valve Replacement or Repair
por: Mentias, Amgad, et al.
Publicado: (2022)

Anticoagulation for Atrial Fibrillation in Patients with Decompensated Liver Cirrhosis: Bold and Brave?
por: Gîrleanu, Irina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_86t73e9e2lqsj80lt95q4n33t5